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Abstract
Objective: Depression may be a risk factor for coronary heart 
disease (CHD) morbidity and mortality, but the mechanism(s) for the 
association are not established.  The present study examined the 
relationship between one possible mechanism, hemostatic factors, 
and depressive symptoms in middle-aged women. Method: We 
measured levels of fibrinogen, Factor VIIc, plasminogen activator 
inhibitor antigen-1 (PAI-1), and tissue plasminogen activator 
antigen (TPA-ag) in 3,016 women aged 42-52 years enrolled in the 
Study of Women’s Health Across the Nation (SWAN). Depressive 
symptoms were measured by the Center for Epidemiological 
Studies Depression Scale (CES-D), with scores > 16 suggestive of 
depression. Results:  Depressed women had high levels of all four 
hemostatic factors ( all p <0 .01). After controlling for age, smoking, 
ethnicity, prevalent cardiovascular disease, osteoarthritis, and dia-
betes, and use of medications (including psychotropics), depressed 
women still had elevated levels of fibrinogen (mean, 95% confidence 
intervals 299, 304 – 295 mg/dl vs. 291, 294 – 288mg/dl, p= 0.003) 
and Factor VIIc (124, 127 – 121 ng/dl vs. 119, 121 – 117 ng/dl,  p= 
0.01) levels, compared to nondepressed women.  Conclusions: 
These findings suggest that hemostatic factors may be a key me-
chanism accounting for the relationship between depression and 
CHD. [Castilla RC, Bromberger JT, Zhang Y, Perel JM, Matthews 
KA. Depressive symptoms are related with hemostatic factors in 
middle-aged women: A report from the Study of Women Health 
Across the Nation (SWAN). MedUNAB 2004; 7:57-64]
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Introduction
Depression may be a risk factor for coronary heart 
disease (CHD) morbidity and mortality, particularly in 
coronary patients.1-3 Among the possible mechanisms 
offered to account for the association are poor adherence 
to medical regimens, unhealthy life style, parasympathetic 
nervous system abnormalities, endothelial dysfunction, 
platelet reactivity and coagulation factors.4-7 Previous 
studies identified an increased rate of perimenopausal 
depression, mostly in women who had had a history of 
depression. These studies lend support to a vulnerability 
theory-women who have previously had affective disorders 
may be at increased risk of mood disturbance during the 
menopausal transition. 1
Little data are available about the relationship between 
depression and hemostatic factors.  In healthy adults, 
higher circulating levels of inteleukin-6, C-reactive 
protein, and tumor necrosis factor-alpha, are associated 
with depression, in part because of obesity.4 Some 
antidepressant medications (e.g. selective serotonin 
reuptake inhibitors) are associated with reduced 
cardiovascular mortality among patients with major 
depression.8, 9 Also supporting the hypothesized 
relationship between depression and hemostatic factors 
are data regarding platelet activation because of the 
interrelationship between the platelet and coagulation 
cascade. Patients with major depression exhibit greater 
platelet activation and higher procoagulant properties 
than do healthy controls.10  They also exhibit more 
binding sites relevant to platelet physiology, including 
imipramine, paroxetine, and inositol on the platelet 
surface. Platelet monoamine oxidase activity is elevated 
in depressed patients, especially in women.11   
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In the present study, we evaluated the association 
of depressive symptoms and fibrinogen, Factor VIIc, 
plasminogen activator inhibitor (PAI-1), and tissue 
plasminogen activator antigen (tPA-ag) levels in 
a multiethnic cohort of middle-aged women. We 
hypothesized that women with elevated depressive 
symptoms would have high levels of hemostatic factors. 
Further, we expected that these differences would be 
maintained after controlling for other factors that affects 
hemostasis (i.e., age, ethnicity, BMI, smoking status; 
history of diabetes mellitus, CHD and hypertension; 
and use of medications for cardiovascular diseases and 
diabetes and for psychiatric illness).  
Methods
Participants. 3304 participants were enrolled in the 
Study of Women’s Health across the Nation (SWAN), a 
multi-site, longitudinal cohort study of the perimenopausal 
transition. Eligibility criteria were ages 42 to 52 years; 
intact uterus and at least 1 ovary; no current use of 
reproductive hormones or other medications known to 
affect ovarian function; at least one menstrual period in 
the 3 months before screening, and self-identification as 
a member of one of the five eligible ethnic groups: Black 
or African American, non-Hispanic White, Chinese or 
Chinese American, Japanese or Japanese American, or 
Hispanic (Cuban American, Dominican, Puerto Rican, 
South American or Spanish).   Women were enrolled at 
7 clinical sites in the following geographic areas: Boston, 
MA, Chicago, IL, Detroit area in Michigan, Los Angeles, 
CA, Hudson County, NJ, Oakland, CA, and Pittsburgh, 
PA. Recruitment techniques were designed to generate 
a representative sample of Caucasian and one minority 
group at each site. The appropriate institutional review 
boards approved this study, and all subjects provided 
written informed consent.  Details of recruitment 
strategies and participant characteristics are described 
elsewhere.12 Of the 3304 participants, 3202 supplied blood 
for further assay; 3016 met minimal criteria for inclusion 
in the analysis, i.e. had complete data for age, ethnicity, 
smoking status, body mass index, and at least one of the 
hemostatic variables that are the focus of this report.  
Protocol. After an initial survey for eligibility criteria 
and general health status, eligible women were invited 
to join SWAN and a baseline evaluation was scheduled. 
The baseline evaluation included a fasting blood draw 
targeted to occur within days 2 – 7 of the menstrual cycle 
and prior to 10 a.m.; measurement of height, weight, 
waist circumference, and blood pressure; interviews 
regarding medical history and lifestyle; and self-report 
questionnaires. Instruments used in this study were 
translated into Cantonese, Japanese, and Spanish.  Study 
design included annual follow-up evaluations thereafter. 
Measures. Depressive symptoms were assessed by the 
Center for Epidemiologic Studies Depression Scale (CES-
D), a 20-item scale that asks about the frequency of being 
bothered by depressive symptoms during the previous 
week.13   We categorized women into those with scores ≥ 
16  vs  < 16, a classification that has been used to identify 
potential clinical depression in community samples.14,15 
The CES-D is a valid and reliable instrument in diverse 
ethnic populations, including African American, Chinese, 
Japanese, and Hispanics.  Internal reliability in SWAN 
was 0.90, ranging from 0.88 – 0.90 in each ethnic group 
taken separately.16-20 
Blood was anticoagulated with 3.8 percent trisodium 
citrate (9:1 vol/vol) and cooled on ice until centrifugation. 
Plasma was separated by centrifugation for 20 minutes at 
2000 g and stored at -80°C for later analysis. Fibrinogen 
and Factor VIIc were measured using a clot-based 
turbidometric detection system, with Factor VIIc assay 
using Factor VII deficient plasma in preparing the 
standard curve.  tPA-ag was measured in plasma using 
a double antibody in an enzyme-linked immunosorbant 
assay (American Diagnostica, Greenwich, CT), with a 
single chain tPA as a standard calibrated against an 
international standard (Hertfordshire, England).  PAI-1 
was measured using a solid phased monoclonal antibody 
and an enzyme labeled goal second antiserum for detection 
(American Diagnostica, Greenwich, CT).  
Weight was measured in light indoor clothing with 
shoes removed using a balance beam scale, and height 
was measured using a stadiometer. Body mass index 
(BMI) was calculated as weight in kilograms divided 
height in meters squared; participants were classified 
as underweight, normal weight, and overweight by the 
National Heart, Lung and Blood Institute (NHLBI) 
criteria. Trained technicians measured blood pressure 
three times for each woman after she was seated for at 
least 5 minutes and the last two readings were averaged. 
Participants were classified as having high blood pressure 
if they had systolic blood pressure > 140 mmHg or a 
diastolic blood pressure > 90 mmHg or were taking anti-
hypertensive medication currently. Participants were 
asked if they had been told by a health care professional 
that they had any of 23 illnesses or conditions and about 
their current medication use.    
Statistical methods. Chi-square or t-tests were used 
to assess univariate association between depression and 
age, ethnicity, BMI, and smoking status. Included as 
potential covariates, were those illnesses and conditions 
commonly associated with heart and inflammatory 
diseases. Covariates included report of history of heart 
disease or using medications to treat heart disease 
(n=95); hypertension (n=578); osteoarthritis (n=592); 
and diabetes mellitus  or use of insulin (n=150);  use of 
anti-coagulant  medications in the last 24 hours (n=20); 
use of pain medications (n=379); and use of psychotropics 
(n=296), i. e.,  tricyclic antidepressant, selective serotonin 
reuptake inhibitors (SSRIs), a selective noradrenergic 
reuptake inhibitor (SNRIs), lithium, anticonvulsivants, 
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benzodiazepines, barbiturates, sleeping pills or other 
sedative/hypnotic.
Those covariates that were significant in the univariate 
analyses were included in the multivariate analyses. 
Final multivariate models were conducted in a backward 
step-wise fashion, such that the covariates were removed 
that were nonsignificant, with CES-D scores remaining 
in the model.  Statistical tests for two-way interactions 
between CES-D score and use of psychotropic medications 
were also included but none was significant and they are 
not discussed further.  Two-sided p-values ≤ 0.05 were 
considered statistically significant. There were 3011, 
2964, 2968, and 2945 women in the analyses of fibrinogen, 
Factor VIIc, tPA-ag, and PAI-1, respectively.  
Results
The mean age of the group was 45.9 + 2.7 years, with 
11% older than 50. By study design almost half the 
women were Caucasian (47.1%), with approximately 
one-quarter African-American, and equal numbers of 
Hispanic, Japanese, and Chinese. The prevalence of 
elevated depressive symptoms was 24.4% in the analytic 
sample. 
Compared with women with low CES-D scores, women 
with elevated scores were younger and were more likely 
to smoke and to be overweight or underweight.  Depressed 
women were more likely to report having heart disease and 
hypertension, or using medications for these conditions, 
and having osteoarthritis and using psychotropic or pain 
medications (table 1). 
Depressed women had elevated coagulation factors 
compared with non-depressed women (figure 1), all 
p<0.01 in univariate analyses. After statistical 
adjustment for the relevant covariates of age, ethnicity, 
BMI, smoking status, high blood pressure, diabetes, 
arthritis, and medication use, depressed women, 
compared to nondepressed women, still had elevated 
fibrinogen levels, mean (95% confidence intervals) 299 
(304–295) vs. 291 (294–289), p=0.003, and Factor VIIc 
levels, mean (95% confidence intervals) 124 (127–121) 
vs. 119 (121–118), p=0.01. However, depression was 
no longer associated with tPA-ag, p=0.85, and PAI-1, 
p=0.39, after covariate adjustment. Use of psychotropic 
medications was significant in the multivariate analyses 
of PAI-1, p=0.006 (table 2). 
Depressed women who were currently using any 
psychotropic medication (n=151) did not have a higher 
level of fibrinogen, 307 vs. 303 mg/dl p=0.59, compared 
with non-users who were depressed. 
Levels of all coagulation factors were higher in older 
women, heavier women, and current smokers (table 2).  
As reported elsewhere (Matthews et al., submitted, 2003), 
fibrinogen levels were highest in African-American women 
(p < 0.005 vs all other groups), and the other levels were 
higher in Hispanics than in Caucasians. Japanese and 
Chinese women exhibited the lowest levels of coagulation 
factors. Women with elevated fasting glucose levels had 
elevated levels of hemostatic factors. 
Discussion
This study is the first to report that elevated fibrinogen 
and Factor VIIc levels are associated with depressive 
symptoms, after adjustment for many covariates, in 
women with diverse ethnic backgrounds. Inflammatory 
and coagulation processes are thought to play a key role 
in coronary artery disease and its sequalae, although 
there is discussion whether they are markers of disease 
or play a causal role. Epidemiological studies show 
associations between risk for CHD and fibrinogen,21,22 
FVII clotting activity,22,23 FVIII clotting activity,24  vWF 
antigen,24,25  t-PA antigen,25,26 PAI-1 antigen,27 D-dimer,28-
30 and plasmin-[alpha]2-antiplasmin complex.29,30 In 
turn, altered fibrinolytic capacity reflected by t-PA 
activity22,23,30 and prolonged euglobulin clot lysis time22 as 
well as low antithrombin III consumed in anticoagulant 
processes with severe atherosclerosis22,23 may all 
prospectively be associated with CHD.  Epidemiological 
studies show that patients with depressive symptoms 
are at increased risk for developing CHD,31-35 and 
cerebrovascular disease,36 although several recent 
reports differ.37,38 Indeed, of patients with CHD, 16% 
to 23% exhibit symptoms of major depression2,39,40 with 
the presence of depression predictive of future cardiac 
complications32,33,39 and diminishing survival time.2,41  
Depressive symptoms may contribute to the onset and 
the maintenance of a chronic inflammatory response to 
injuries to the endothelium through maladaptive health 
practices such as cigarette smoking.4 However, our analy-
ses adjusted for the effects of lifestyle factors, so this is an 
unlikely explanation of our results.  Similarly, depression 
appears to increase susceptibility to infection with latent 
pathogens that colonize the vessel wall42 but, as best we 
could, we controlled for prevalent disease and use of 
relevant medications through history. Stress triggers 
dysregulation of the neurohormonal system responsible 
for cortisol and catecholamine secretion.43 Elevations in 
plasma catecholamines may increase platelet activity in 
depressed women and, in turn, lower the threshold for 
myocardial ischemia, and increase the risk of coronary 
thrombosis.10,44,49 Each of these processes could damage 
the endothelium, thereby triggering inflammatory/
coagulation processes that contribute to the progression 
of atherosclerosis.44,45,48
Several limitations deserve comment. First, the analysis 
presented here is cross-sectional.  Thus, cause and effect 
relationships cannot be proven.  Second, the hemostatic 
variable levels were determined at only one point in time 
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Table 1. Sample of women according to depression (CES-D) scores.
Characteristics Total CES-D < 16 CESD > 16 P-value for 
depression
Demographic factors N % N % N %
Age 0.0001
< 45 1443 48 1045 46 398 54
45 – 49 1238 41 962 42 276 38
> 50 335 11 274 12 61 8
Ethnicity <0.0001
Black 848 28 619 27 229 31
Hispanic 248 8 138 6 110 15
Chinese 234 8 201 9 33 5
Japanese 264 9 224 10 40 5
White 1422 47 1099 48 323 44
BMI (kg/m2) 0.0003
< 18.5 48 2 38 2 10 2
18.5 – 24.9 1161 38 923 40 238 32
> 25 1807 60 1320 58 487 66
Smoking Status <0.0001
Current 521 17 341 15 180 25
Past 755 25 578 25 177 24
Never 1740 58 1362 60 378 51
High Blood Pressure    
     Yes 578 19 415 18 163 22 0.02
     No 2438 81 1866 82 572 78
Diabetes 
     Yes 150 5 105 5 45 6 0.010
     No 2866 95 2176 95 690 94
Coronary Heart Disease 
     Yes 95 3 54 3 41 6 <0.0001
     No 2921 97 2227 97 694 94
Osteoarthritis 
     Yes 592 20 392 17 200 27 <0.0001
     No 2424 80 1889 83 535 73
Anticoagulant Medication
     Yes 20 1 11 1 9 1 0.03
     No 2996 99 2270 99 726 99
Psychotropics
     Yes 296 10 157 7 139 19 <0.001
     No 2720 90. 2124 93 596 81
Pain medication
     Yes 357 12 234 10 123 17 <0.001
     No 2659 88 2047 90 612 83
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and the platelet measures were not included. Third, 
although we measured many potential confounding va-
riables, the association between depressive symptoms 
and increase in coagulation factors concentration may be 
influenced by unmeasured variables. Fourth, we measu-
red depressive symptoms rather than diagnosing clinical 
depression via interview. Thus, we must conclude that 
depressive symptoms, not the diagnosis of depression, are 
associated with increased hemostatic variables. 
This study is the first report in a community-dwelling sample 
of mid-life women of an association of hemostatic variables 
and depressive symptoms. Although depression is common 
among women, most cases go unrecognized or undertrea-
ted.46,47 If treatment for depression were effective in reducing 
the coagulation levels50, then better diagnosis and treatment 
of depression may decrease cardiovascular morbidity and 
mortality associated with the hypercoagulatory state.
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Table 2. Fibrinogen, Factor VIIc, PAI-1 and TPA levels according to depressive symptoms and covariates; significance values from mul-











     > 16 304 (73)** 125 (54)** 31 (32) 8 (3)
     <16 290(66) 119 (36) 28 (29) 8 (3)
Age
     < 45 291 (67)* 119 (40)** 28 (31) 8 (3)**
     45 - 49 294 (69) 120 (36) 28 (28) 8 (3)
     > 50 301 (71) 129 (60) 30 (31) 8 (3)
Ethnicity
     Black 314 (73)**** 117 (36)**** 31 (33)** 9 (3)**
     Hispanic 290 (69) 129  (43) 36 (31) 9 (3)
     Chinese 273 (46) 113 (21) 24 (22 ) 7 (3)
     Japanese 256 (57) 119 (42) 23 (20) 7 (3)
     White 292 (66) 123 (46) 27 (30) 7 (3)
BMI (kg/m2)
     < 18.5 252 (56)**** 103 (23)**** 16 (27)**** 6 (3)****
     18.5 - 25 266 (53) 112 (35) 18 (16) 6 (3)
     > 25 312 (71) 126  (44) 35 (34) 9 (3)
Smoking status
     Current 311 (74)*** 123 (45)* 32 (34) 8 (3)***
     Past 293 (71) 124 (43) 29  (33) 8  (3)
     Never 288 (64) 118 (39) 27 (27) 8 (3)
High blood pressure
          Yes 313 (74) 127 (42)** 38 (38 )**** 10 (3)****
          No 289 (66) 119 (41) 26 (27) 7 (3)
Diabetes 
     Yes 321 (68)** 131 (32)* 40 (45)* 10 (4)****
     No 292 (68) 120 (41) 28 (29) 8 (3)
Coronary heart disease 
    Yes 322 (86)* 124 (35) 42 (53 )* 9 (4)
     No 292  (68) 120  (41) 28 (29) 8 (3)
Osteo-Arthritis  
     Yes 305 (72) 124 (42) 35 (40)** 9 (4)*
     No 290  (67) 120 (41) 27 (26) 8 (3)
Anticoagulant medications
     Yes 318 (57) 121 (41) 39 (30) 9 (4 )
     No 293 (68) 120 (41) 28 (30) 8 (3)
Psychotropics      
     Yes 307 (74) 129 (41)* 35 (43)** 8 (4)
     No 292 (68) 119 (41) 27 (28) 8 (3)
Pain medications
     Yes 303 (76) 124 (39) 35 (40)** 8 (3)
     No 292 (67) 120 (41) 27 (28) 8 (3)
Note: Unadjusted mean and standard deviation. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 from final multivariate models using backward step-wise regression.
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